Literature DB >> 11019784

IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis.

M Royuela1, M P De Miguel, F R Bethencourt, B Fraile, M I Arenas, R Paniagua.   

Abstract

The presence of interleukin-2 (IL-2) and its receptors (Ralpha, Rbeta, Rgamma), and their relationship with the products of bcl-2 and bax genes was studied in normal prostates, benign prostatic hyperplasia (BPH), and prostatic cancer (PC) by ELISA, Western blot, and immunohistochemistry. A comparative semiquantitative immunohistochemical study was also performed. For all the antibodies assayed, immunoreactions were found in the epithelium and some stromal cells in the three types of specimens studied. These immunoreactions were much more higher in PC samples than in normal prostates. In BPH, immunoreactions were similar to that of normal prostates (bax), similar to that of PC (IL-2 and its three receptors), or intermediate between that of normal prostates and that of PC (bcl-2). Immunoexpressions of IL-2 and its receptors were found in the epithelial basal cells and some stromal cell of normal prostates and might be related to the control of the proliferation-apoptosis equilibrium. The increased expressions of IL-2 and its receptors in the epithelium of prostates in BPH, associated with increased bcl-2 expression which would account for the decrease in the apoptosis index that has been reported in this disorder. The increased expression of both bcl-2 and bax in PC might be involved in the higher apoptosis index reported in PC specimens. Since IL-2 administration seems to have an anti-tumour effect, the increased expression of this interleukin in BPH and PC could be interpreted as an attempt to hinder cell proliferation which would only be efficient at high doses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11019784     DOI: 10.3109/08977190009003239

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  7 in total

1.  IL-2 gene C/T polymorphism is associated with prostate cancer.

Authors:  Hsi-Chin Wu; Chao-Hsiang Chang; Lei Wan; Chao-I Wu; Fuu-Jen Tsai; Wen-Chi Chen
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

Review 2.  The functional role of reactive stroma in benign prostatic hyperplasia.

Authors:  Isaiah G Schauer; David R Rowley
Journal:  Differentiation       Date:  2011-06-12       Impact factor: 3.880

3.  Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).

Authors:  Kuo-Pao Lai; Chiung-Kuei Huang; Lei-Ya Fang; Kouji Izumi; Chi-Wen Lo; Ronald Wood; Jon Kindblom; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Endocrinol       Date:  2013-07-26

4.  Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer.

Authors:  Jennifer S Myers; Ariana K von Lersner; Charles J Robbins; Qing-Xiang Amy Sang
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240

5.  Suppression of Cisplatin-Induced Hepatic Injury in Rats Through Alarmin High-Mobility Group Box-1 Pathway by Ganoderma lucidum: Theoretical and Experimental Study.

Authors:  Hanan M Hassan; Lamya H Al-Wahaibi; Mohammed A Elmorsy; Yasmen F Mahran
Journal:  Drug Des Devel Ther       Date:  2020-06-11       Impact factor: 4.162

6.  Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate.

Authors:  Gonzalo Rodríguez-Berriguete; Benito Fraile; Fermín R de Bethencourt; Angela Prieto-Folgado; Nahikari Bartolome; Claudia Nuñez; Bruna Prati; Pilar Martínez-Onsurbe; Gabriel Olmedilla; Ricardo Paniagua; Mar Royuela
Journal:  BMC Cancer       Date:  2010-01-15       Impact factor: 4.430

7.  Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study.

Authors:  Ignacio García-Tuñón; Mónica Ricote; Antonio Ruiz; Benito Fraile; Ricardo Paniagua; Mar Royuela
Journal:  Breast Cancer Res       Date:  2003-10-22       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.